Cenix BioScience has named Zisi Fotev as its new chief business officer.
Fotev joins Cenix from Atugen, where he served as vice president of business development. Prior to this, Cenix said, he served as head of licensing and strategic alliances at the pharmaceuticals division of Germany’s Merck.
Fotev holds a BS from the University of Western Australia and a PhD from the University of Tuebingen.
Qiagen said this week that it has appointed Noel Thomas Doheny as its vice president of solutions for molecular diagnostics. Doheny will be part of Qiagen’s new executive team and report directly to CEO Peer Schatz.
According to Qiagen, Doheny formerly served in key positions for ThermoBioStar, including president and director of strategic planning and business development.
In the latest issue of MIT’s Technology Review magazine, Rockefeller University researcher Thomas Tuschl was interviewed for an article highlighting RNA interference.
Also interviewed for the piece is John Rossi of the Beckman Research Institute of the City of Hope Cancer Center.